Reporting of Incidence and Outcome of Bone Metastases in Clinical Trials Enrolling Patients with Epidermal Growth Factor Receptor Mutated Lung Adenocarcinoma-A Systematic Review

Anita Brouns, Safiye Dursun, Gerben Bootsma, Anne-Marie C. Dingemans, Lizza Hendriks*

*Corresponding author for this work

Research output: Contribution to journalReview articleAcademicpeer-review

Original languageEnglish
Article number3144
Number of pages20
JournalCancers
Volume13
Issue number13
DOIs
Publication statusPublished - Jul 2021

Keywords

  • non-small cell lung cancer
  • lung adenocarcinoma
  • epidermal growth factor mutation
  • bone metastases
  • skeletal-related events
  • epidermal growth factor receptor mutation
  • tyrosine kinase inhibitor
  • 1ST-LINE TREATMENT
  • OPEN-LABEL
  • EGFR MUTATIONS
  • PHASE-II
  • INTRAVENOUS BISPHOSPHONATES
  • INTERCALATED CHEMOTHERAPY
  • PROSTATE-CANCER
  • ADVANCED NSCLC
  • SINGLE-ARM
  • CELL

Cite this